CHALLENGING PROBLEMS OF HYPERTENSION MANAGEMENT: THE EFFECT OF INCREASED HEART RATE AND COMORBIDITIES ON THE CHOICE OF ANTIHYPERTENSIVE THERAPY IN PRACTICE OF CARDIOLOGIST AND THERAPIST. The Conclusion of the Expert Council

The conclusion of the Expert Council "Challenging problems of hypertension management: the effect of increased heart rate and comorbidities on the choice of antihypertensive therapy in practice of cardiologist and therapist" is presented. Topical issues of hypertensive patient’s treatment, the role of heart rate in hypertension and ways to influence it are considered. The possibility of treatment of hypertensive patients with trandolapril/verapamil SR fixed combination is analyzed separately. The data on the clinical efficacy and protective effects of trandolapril/verapamil SR fixed combination are presented.

1. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Russian Medical Society of hypertension. Russian Scientific Society of Cardiology. Sistemnye Gipertenzii 2010; 3: 5-26. Russian (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Российское медицинское общество по артериальной гипертонии. Всероссийское научное общество кардиологов. Системные Гипертензии 2010;3:5-26).

2. Kotchen TA. Hypertensive vascular disorders. In: Longo DL., Fauci AS., Kasper DL., Hauser SL., Jameson JL., Loscalzo J., eds. Harrison’s Principles of Internal Medicine. Vol 2. 18th ed. New York, NY: Mc-Graw-Hill; 2012: 2042-59.

3. Clinical Management of Primary Hypertension in Adults. National Institute for Clinical Health and Excellence. Available at: http://guidance.nice.org.uk/CG127/NICEGuidance/pdf/English. Accessed by 13.12. 2014.

4. The incidence of the entire population of Russia in 2012. Statistical materials. Available on http://www.rosminzdrav.ru/docs/mzsr/stat/47. Accessed by 12.12.2014. Russian (Заболеваемость всего населения России в 2012 году. Статистические материалы. Доступно на http://www.rosminzdrav.ru/docs/mzsr/stat/47. Дата доступа 12.12.2014).

5. Shalnova S, Kukushkin S, Manoshkina E, Timofeeva G. Hypertension and commitment therapy. Vrach 2009; 12: 39-42. Russian (Шальнова С., Кукушкин С., Маношкина Е., Тимофеева Г. Артериальная гипертензия и приверженность терапии. Врач 2009; 12:39-42).

6. Mancia G, Fagard R, Nerkiewicz K, et al. 2013 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-357.

7. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by twodrug combination as first step. Evidence from daily life practice. J Hypertens 2010;28(7):1584-90.

8. Zagrebel'nyi AV, Martsevich SY, Lukyanov MM, et al. Evaluation of the quality of antihypertensive drugs in patients with arterial hypertension without concomitant cardio - vascular disease, in the framework of outpatien-polyclinic register REKVAZA. Ration Pharmacother Cardiol 2014; 10 (4): 378-83. Russian (Загребельный А.В., Марцевич С.Ю., Лукьянов М.М., и др. Оценка качества назначения антигипертензивных препаратов больным артериальной гипертонией, не имеющих сочетанной сердечно - сосудистой патологии, в рамках амбулаторно-поликлинического регистра РЕКВАЗА. Рациональная Фармакотерапия в Кардиологии 2014;10(4):378-83).

9. Gillman MW., Kannel WB., Belanger A., D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125(4):1148-54.

10. Chobanian AV., Bakris GL., Black HR. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (2003). The JNC 7 report. Hypertension 2003; 42 (6): 1206 - 52.

11. Farinaro E. An Italian study on heart rate in hypertensives. Ann Ital Med Int 1994;9 Suppl:27S-28S.

12. Wiysonge C.S., Opie L.H. β-Blockers as initial therapy for hypertension. JAMA 2013;310:1851-2.

13. Lindholm LH., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366(9496):1545-53.

14. James PA., Oparil S., Carter BL., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5):507-20.

15. Zou Z., Xu F-Y., Wang L., et al. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials. Journal of Human Hypertension 2011; 25: 203-10.

16. Fox K., Ford I., Steg PG., et al.; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371(12):1091-9.

17. Instructions for use of the drug for medical use Tarka® 2/180 mg of 15/07/2014. Available at: http://grls.rosminzdrav.ru/ScanVavilova/Vneseno_v_Grls/430931/IP/nina064.jpg. Accessed by 17/02/2015. Russian (Инструкция по применению лекарственного препарата для медицинского применения Тарка® 2/180 мг от 15.07.2014. Доступно на: http://grls.rosminzdrav.ru/Scan-Vavilova/Vneseno_v_Grls/430931/IP/nina064.jpg. Проверено 17.02.2015).

18. Instructions for use of the drug for medical use Tarka® 4/240 mg of 15/07/2014. Available at: http://grls.rosminzdrav.ru/ScanVavilova/Vneseno_v_Grls/430931/IP/nina064.jpg. Accessed by 17/02/2015. Russian (Инструкция по применению лекарственного препарата для медицинского применения Тарка® 4/240 мг от 31.03.2014. Доступно на: http://grls.rosminzdrav.ru/Scan-Vavilova/Vneseno_v_Grls/430931/IP/nina064.jpg. Проверено 17.02.2015).

19. Certificate of registration of the drug Tarka 4/240 mg number LP-001791 - 31/03/14 Health Ministry. Available at: http://grls.rosminzdrav.ru/Grls_View.aspx?idReg=138099&isOld=0&t=. Accessed by 17/02/2015. Russian (Регистрационное удостоверение лекарственного препарата Тарка 4/240 мг № ЛП-001791 – 31.03.14 МЗ РФ. Доступно на: http://grls.rosminzdrav.ru/Grls_View.aspx?idReg=138099&isOld=0&t=. Проверено 17.02.2015).

20. Ruggenenti P., Fassi A., Parvanova Ilieva A., et al. Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351(19):1941-51.

21. Bakris GL., Weir MR., Secic M., et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65 (6): 1991-2002.

22. Køber L, Torp-Pedersen C, Carlsen JE et al. for the Trandolapril Cardiac Evaluation (TRACE) Study. A clinical trial of the angiotensin – converting enzyme inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333(25):1670-6.

23. Pepine CJ., Handberg-Thurmond E., Marks R., et al. for the INVEST investigators. Rationale and Design of the International Verapamil SR/Trandolapril Study (INVEST): An Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998; 32(5):1228-37.

24. Cooper-DeHoff R. Cohen JD, Bakris GL, et al. for INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the International Verapamil SR-Trandolapril Study [INVEST]. Am J Cardiol 2006; 98:890-4.